Browse AMER1

Summary
SymbolAMER1
NameAPC membrane recruitment protein 1
Aliases RP11-403E24.2; FLJ39827; WTX; Wilms Tumor on the X; adenomatous polyposis coli membrane recruitment 1; FAM12 ......
Chromosomal LocationXq11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Nucleus. Note=Shuttles between nucleus and cytoplasm. Detected in nuclear paraspeckles that are found close to splicing speckles. Translocates to the cell membrane following binding to PtdIns(4,5)P2.
Domain PF09422 WTX protein
Function

Regulator of the canonical Wnt signaling pathway. Acts by specifically binding phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2), translocating to the cell membrane and interacting with key regulators of the canonical Wnt signaling pathway, such as components of the beta-catenin destruction complex. Acts both as a positive and negative regulator of the Wnt signaling pathway, depending on the context: acts as a positive regulator by promoting LRP6 phosphorylation. Also acts as a negative regulator by acting as a scaffold protein for the beta-catenin destruction complex and promoting stabilization of Axin at the cell membrane. Promotes CTNNB1 ubiquitination and degradation. Involved in kidney development.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001655 urogenital system development
GO:0001822 kidney development
GO:0009894 regulation of catabolic process
GO:0009896 positive regulation of catabolic process
GO:0010498 proteasomal protein catabolic process
GO:0016055 Wnt signaling pathway
GO:0030111 regulation of Wnt signaling pathway
GO:0030177 positive regulation of Wnt signaling pathway
GO:0030178 negative regulation of Wnt signaling pathway
GO:0031329 regulation of cellular catabolic process
GO:0031331 positive regulation of cellular catabolic process
GO:0031396 regulation of protein ubiquitination
GO:0031398 positive regulation of protein ubiquitination
GO:0032984 macromolecular complex disassembly
GO:0042176 regulation of protein catabolic process
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
GO:0043241 protein complex disassembly
GO:0045732 positive regulation of protein catabolic process
GO:0048762 mesenchymal cell differentiation
GO:0060070 canonical Wnt signaling pathway
GO:0060348 bone development
GO:0060485 mesenchyme development
GO:0060612 adipose tissue development
GO:0060828 regulation of canonical Wnt signaling pathway
GO:0061005 cell differentiation involved in kidney development
GO:0061448 connective tissue development
GO:0072001 renal system development
GO:0072074 kidney mesenchyme development
GO:0072161 mesenchymal cell differentiation involved in kidney development
GO:0090090 negative regulation of canonical Wnt signaling pathway
GO:0090263 positive regulation of canonical Wnt signaling pathway
GO:0198738 cell-cell signaling by wnt
GO:1903320 regulation of protein modification by small protein conjugation or removal
GO:1903322 positive regulation of protein modification by small protein conjugation or removal
GO:1903362 regulation of cellular protein catabolic process
GO:1903364 positive regulation of cellular protein catabolic process
GO:1904885 beta-catenin destruction complex assembly
GO:1904886 beta-catenin destruction complex disassembly
GO:2001012 mesenchymal cell differentiation involved in renal system development
Molecular Function GO:0005543 phospholipid binding
GO:0005546 phosphatidylinositol-4,5-bisphosphate binding
GO:0008013 beta-catenin binding
GO:0035091 phosphatidylinositol binding
GO:1901981 phosphatidylinositol phosphate binding
GO:1902936 phosphatidylinositol bisphosphate binding
GO:1904713 beta-catenin destruction complex binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-4839748: AMER1 mutants destabilize the destruction complex
R-HSA-5467337: APC truncation mutants have impaired AXIN binding
R-HSA-5467340: AXIN missense mutants destabilize the destruction complex
R-HSA-4839735: AXIN mutants destabilize the destruction complex, activating WNT signaling
R-HSA-196299: Beta-catenin phosphorylation cascade
R-HSA-195253: Degradation of beta-catenin by the destruction complex
R-HSA-5467343: Deletions in the AMER1 gene destabilize the destruction complex
R-HSA-4641262: Disassembly of the destruction complex and recruitment of AXIN to the membrane
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-5339716: Misspliced GSK3beta mutants stabilize beta-catenin
R-HSA-5358747: S33 mutants of beta-catenin aren't phosphorylated
R-HSA-5358749: S37 mutants of beta-catenin aren't phosphorylated
R-HSA-5358751: S45 mutants of beta-catenin aren't phosphorylated
R-HSA-162582: Signal Transduction
R-HSA-4791275: Signaling by WNT in cancer
R-HSA-195721: Signaling by Wnt
R-HSA-5358752: T41 mutants of beta-catenin aren't phosphorylated
R-HSA-201681: TCF dependent signaling in response to WNT
R-HSA-5467348: Truncations of AMER1 destabilize the destruction complex
R-HSA-4839743: phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
R-HSA-4839744: truncated APC mutants destabilize the destruction complex
Summary
SymbolAMER1
NameAPC membrane recruitment protein 1
Aliases RP11-403E24.2; FLJ39827; WTX; Wilms Tumor on the X; adenomatous polyposis coli membrane recruitment 1; FAM12 ......
Chromosomal LocationXq11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between AMER1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolAMER1
NameAPC membrane recruitment protein 1
Aliases RP11-403E24.2; FLJ39827; WTX; Wilms Tumor on the X; adenomatous polyposis coli membrane recruitment 1; FAM12 ......
Chromosomal LocationXq11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of AMER1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolAMER1
NameAPC membrane recruitment protein 1
Aliases RP11-403E24.2; FLJ39827; WTX; Wilms Tumor on the X; adenomatous polyposis coli membrane recruitment 1; FAM12 ......
Chromosomal LocationXq11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of AMER1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1790.386
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.020.964
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3210.398
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2670.262
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3020.878
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.220.932
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.7620.00811
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4140.657
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.1490.269
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1440.79
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.90.177
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1030.143
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of AMER1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.93.74.20.636
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.27.1-0.91
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolAMER1
NameAPC membrane recruitment protein 1
Aliases RP11-403E24.2; FLJ39827; WTX; Wilms Tumor on the X; adenomatous polyposis coli membrane recruitment 1; FAM12 ......
Chromosomal LocationXq11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of AMER1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolAMER1
NameAPC membrane recruitment protein 1
Aliases RP11-403E24.2; FLJ39827; WTX; Wilms Tumor on the X; adenomatous polyposis coli membrane recruitment 1; FAM12 ......
Chromosomal LocationXq11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of AMER1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by AMER1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolAMER1
NameAPC membrane recruitment protein 1
Aliases RP11-403E24.2; FLJ39827; WTX; Wilms Tumor on the X; adenomatous polyposis coli membrane recruitment 1; FAM12 ......
Chromosomal LocationXq11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of AMER1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolAMER1
NameAPC membrane recruitment protein 1
Aliases RP11-403E24.2; FLJ39827; WTX; Wilms Tumor on the X; adenomatous polyposis coli membrane recruitment 1; FAM12 ......
Chromosomal LocationXq11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of AMER1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolAMER1
NameAPC membrane recruitment protein 1
Aliases RP11-403E24.2; FLJ39827; WTX; Wilms Tumor on the X; adenomatous polyposis coli membrane recruitment 1; FAM12 ......
Chromosomal LocationXq11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between AMER1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolAMER1
NameAPC membrane recruitment protein 1
Aliases RP11-403E24.2; FLJ39827; WTX; Wilms Tumor on the X; adenomatous polyposis coli membrane recruitment 1; FAM12 ......
Chromosomal LocationXq11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting AMER1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.